ENO1 (Enolase 1) encodes alpha-enolase, a key glycolytic enzyme also known as phosphopyruvate hydratase. Beyond its well-established role in glycolysis, alpha-enolase has emerged as a multifunctional protein with critical roles in neurodegeneration. It functions as a glycolytic enzyme, stress protein, plasminogen receptor, and autoantigen. The gene is located on chromosome 1p36.23 and encodes a 433-amino acid protein (approximately 47 kDa). ENO1 is ubiquitously expressed but exhibits particularly high levels in neurons and other tissues with high metabolic demand.
| Attribute |
Value |
| Symbol |
ENO1 |
| Full Name |
Enolase 1 (Alpha-enolase) |
| Chromosomal Location |
1p36.23 |
| NCBI Gene ID |
2023 |
| OMIM |
172430 |
| Ensembl ID |
ENSG00000169064 |
| UniProt ID |
P06733 |
Alpha-enolase is a 433-amino acid protein (approximately 47 kDa) that forms homodimers and heterodimers with other enolase isoforms (ENO2, ENO3). The enzyme requires magnesium ions for catalytic activity.
¶ Structural Domains
- N-terminal domain (aa 1-150): Involved in dimerization and protein-protein interactions with various binding partners
- Central domain (aa 151-350): Contains the enolase active site responsible for catalyzing the conversion of 2-phosphoglycerate to phosphoenolpyruvate
- C-terminal domain (aa 351-433): Contains a lysine-rich region that can function as a DNA-binding site and mediates interactions with plasminogen
ENO1 produces multiple isoforms through alternative splicing:
- α-Enolase: The predominant isoform in most tissues
- MiRNA-1: A smaller isoform generated from an internal promoter, localized to the cell surface
Alpha-enolase catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate (PEP), the second-to-last step of glycolysis:
2-Phosphoglycerate + Mg²⁺ → Phosphoenolpyruvate + H₂O + Mg²⁺
This reaction is critical for cellular energy production, particularly in neurons which have high metabolic demands (Song et al., 2009).
- Plasminogen binding: Surface enolase serves as a receptor for plasminogen, linking metabolism to fibrinolysis
- Stress protein: Induced under various stress conditions including hypoxia, oxidative stress, and inflammatory stimuli (Mariga et al., 2012)
- c-Myc binding protein: Functions as a transcriptional repressor influencing gene expression
- Autoantigen: Can trigger autoimmune responses in certain disease contexts
Alpha-enolase has been extensively studied in Alzheimer's disease (AD):
Autoimmune Aspects:
- Anti-ENO1 antibodies have been detected in AD patients' cerebrospinal fluid and serum (Chen et al., 2006)
- These autoantibodies may contribute to disease progression through immune complex formation
- ENO1 is recognized as one of the autoantigens in the "Alzheimer's disease-associated immune repertoire"
Energy Metabolism Dysfunction:
- Reduced enolase activity has been documented in AD brains (Iwata et al., 2004)
- Glycolytic dysfunction is a well-established feature of AD pathogenesis
- Impaired glucose metabolism correlates with cognitive decline
Amyloid Interaction:
- Alpha-enolase may interact with amyloid-beta aggregates (Pan et al., 2020)
- ENO1 has been identified in amyloid plaques in AD brain tissue
- The interaction may influence plaque formation and neurotoxicity
Oxidative Stress:
- Alpha-enolase is highly sensitive to oxidative modification
- Carbonylation of ENO1 has been detected in AD brains
- Oxidative damage to glycolytic enzymes contributes to metabolic dysfunction
In Parkinson's disease (PD), ENO1 plays multiple roles:
Lewy Body Pathology:
- Alpha-enolase has been detected in Lewy bodies in PD brains (Takashima et al., 2021)
- ENO1 colocalizes with alpha-synuclein in these inclusions
- This suggests ENO1 may be involved in the aggregation process
Autoimmunity:
- Anti-ENO1 antibodies have been identified in PD patients (Cho et al., 2003)
- Elevated anti-ENO1 antibody titers correlate with disease severity (Yang et al., 2018)
- ENO1 may serve as a biomarker for PD progression (Liu et al., 2020)
Dopaminergic Neuron Vulnerability:
- ENO1 expression is altered in dopaminergic neurons
- Metabolic dysfunction in these neurons may involve enolase dysregulation
In ALS, ENO1 has been implicated in muscle metabolism:
- Altered enolase expression has been observed in ALS muscle tissue (Polkovnikov et al., 2020)
- ENO1 may serve as a biomarker for disease progression
- Metabolic dysfunction in motor neurons involves glycolytic alterations
Recent research has revealed a role for ENO1 in neuroinflammation:
- ENO1 can activate the TLR4 pathway in microglia (Zhang et al., 2021)
- This triggers pro-inflammatory cytokine release
- ENO1 released from damaged cells may amplify neuroinflammation
- Ubiquitous expression in all human tissues
- Highest levels in tissues with high metabolic activity: brain, muscle, liver
- Neurons: High expression, particularly in cortical and hippocampal neurons
- Astrocytes: Moderate expression
- Oligodendrocytes: Lower expression
- Microglia: Expression increases with activation
- Cytosolic: Primary location for glycolytic function
- Cell surface: Present on plasma membrane as plasminogen receptor
- Nuclear: Some isoforms can translocate to nucleus
Genetic studies have explored ENO1 variants in neurodegenerative diseases:
- ENO1 polymorphisms have been investigated for association with AD and PD
- Some variants may alter protein expression or function
- Further research is needed to confirm genetic links (Hernandez et al., 2018)
ENO1 has potential as a biomarker:
- Anti-ENO1 antibodies in CSF and serum
- ENO1 levels in cerebrospinal fluid
- Plasma ENO1 for early PD detection
- ENO1-directed immunotherapy approaches
- Modulating ENO1 autoimmunity
- Targeting ENO1-mediated neuroinflammation
- Butterfield et al., (2019)
- Zhan et al., Neurology (2018)
- Hafiz et al., Cell Death & Disease (2020)
- Chen et al., Alpha-enolase as autoantigen in AD (2006)
- Cho et al., Enolase 1 in PD (2003)
- Iwata et al., Alpha-enolase as prognostic marker (2004)
- Pasinetti et al., Enolase as biomarker (2002)
- Song et al., Glycolytic dysfunction in AD (2009)
- Mariga et al., Enolase as stress protein (2012)
- Yang et al., Anti-ENO1 autoantibodies in PD (2018)
- Polkovnikov et al., Beta-enolase in ALS (2020)
- Zhang et al., ENO1 promotes neuroinflammation (2021)
- Kim et al., Proteomic analysis of ENO1 in aging brain (2019)
- Liu et al., Plasma ENO1 as PD biomarker (2020)
- Hernandez et al., ENO1 variants in neurodegeneration (2018)
- Pan et al., ENO1 interacts with Aβ (2020)
- Takashima et al., ENO1 in Lewy body formation (2021)